List of Sessions

Incidence trends in HPV-related cancers, effect of vaccine on cancer rates, geographic heterogeneity • Amber D'Souza (USA)

Emerging molecular approaches in cervical screening: A guide for clinicians • Laila Sara Arroyo Mühr (Sweden) - Milan Stosic (Norway)

Cytology-free screening programs: Principles and practice • Partha Basu (France) - Joakim Dillner (Sweden)

HPV vaccination and cervical screening: How and when do we screen vaccinated women for cervical disease and cancer • Kate Cuschieri (UK) - Tim Palmer (UK)

Closing the loops: Implementation solutions for HPV screening in low-resource settings • Silvia de Sanjosé (Spain) - Federica Inturrisi (Italy)

Quality Outcomes after implementation of self-collection in Regional or National cervical screening programs • David Hawkes (Australia)

Bridging the implementation gap in self-sampling for routine cervical cancer screening • Miriam Elfström (Sweden) - Mette Tranberg (Denmark)

New evidence for self-sampling in screening programmes • Clare Gilham (UK) - Marc Arbyn (Belgium)

The utility of urine for improved gynaecological cancer prevention • Renske Steenbergen (Netherlands) - Severien Van Keer (Belgium) - Bart Hesselink (Netherlands)

First-void urine for long-term HPV vaccine impact monitoring in LMICs: Insights from Gavi pilot and national immunization program cohorts in Kenya, Senegal and Uganda • Alex Vorsters (Belgium) - Nelly Mugo (Kenya)

Maximizing the impact of single-dose HPV vaccination to accelerate control of HPV-driven cancers • Aimee R. Kreimer (USA) - Marc Brisson (Canada)

Vaccinating for elimination: Closing the HPV prevention gap • Jiayao Lei (Sweden) - Julia Brotherton (Australia)

Is human papillomavirus vaccination followed by HPV type-replacement? • Matti Lehtinen (Sweden)

HPV vaccination benefits in adult women aged 25-45: Modelling insights synthesis and update • Yao-Hsuan Chen (UK) - Beate Jahn (Austria)

The next frontier in HPV vaccination • Mark Jit (USA)

United for elimination: Country-driven strategies to end cervical cancer • Sharon Hanley (UK) - Miriam Elfström (Sweden)

Overview of the European commission initiative on cervical cancer (EC-CvC) • Katayoun Taghavi (France)

From prevention to elimination: JA SHIELD’s integrated approach to reducing HPV-related cancers across Europe • Dorthe Raben (Denmark) - Sharon Dhillon (Belgium) - Helene De Pauw (Belgium)

Risk stratification in cervical cancer prevention • Paolo Giorgi Rossi (Italy) - Peter Sasieni (UK)

The enigma of cervical adenocarcinoma in situ: The glandular blind spot – Rethinking cervical AIS • Jacob Bornstein (Israel) - Zvi Vaknin (Israel)

From science to clinical decisions: New frontiers in VIN and vulvar cancer prevention • Jacob Bornstein (Israel) - Monika Hampl (Germany)

HPV “treatments”: Evidence, regulation, and guidance for clinicians • Laila Sara Arroyo Mühr (Sweden) - Suzanne Garland (Australia)

The hidden cervix – The invisible SCJ challenge: What do you do when you see nothing? • Silvia de Sanjosé (Spain) - Federica Inturrisi (Italy)

Cervix cancer screening for women over 50 – Clinical and scientific considerations • Miriam Elfström (Sweden) - Gina Ogilvie (Canada)

From laboratory dignal to clinical decision: Using HPV Ct values to guide clinical management • Jiayao Lei (Sweden) - Peter Sasieni (UK)

Optimizing HPV triage strategies: current and emerging options • Joakim Dillner (Sweden) - Nicolas Wentzensen (USA)

Listening and learning: What is people’s real experience with cervical cancer prevention and management? • Martina Alberani (Italy) - Paolo Giorgi Rossi (Italy)

HPV controversies: Challenging current paradigms in prevention and clinical practice • Chair to be confirmed

Pediatric HPV: Transmission, systemic impact, and the reality of RRP • Karolina Louvanto (Sweden) - Helen Trottier (Canada)

Global HPV laboratory network support for cervical cancer elimination: Quality, capacity, validation and innovation • Laila Sara Arroyo Mühr (Sweden) - Clementina Cocuzza (Italy)

Navigating technical challenges and opportunities in the early stages of point-of-care test development • Ella Boswell (UK) - Federica Inturrisi (Italy)

HPV-BRIDGE (HPV – Biomarker Roadmap for Implementing Diagnostics, Guidance and Evaluation) • Chair to be confirmed

Validation of new HPV tests • Marc Arbyn (Belgium) - Clementina Cocuzza (Italy)

Microbiome: What are the next steps? • Mette Tranberg (Denmark) - Anna Barbara Moscicki (USA)

Microbiome, metabolomics and cervical cancer prevention: From HPV natural history to treatment outcomes • Katayoun Taghavi (France)

HPV and the microbiome: Biomarker discovery, mechanisms and opportunities for translational outcomes • Gina Ogilvie (Canada) - Laurie Smith (Canada)

Methylation: Implementation strategies for anogenital cancer screening and beyond • Bart Hesselink (Netherlands) - Renske Steenbergen (Netherlands) - Severien Van Keer (Belgium)

Translating methylation biomarkers into screening programs: From validation to real-world impact • Danielle Heideman (Netherlands) - Bea Wisman (Netherlands)

HPV/cancer prevention in solid organ transplant patients: Vaccination, screening, and future directions • Marc Goodman (USA) - Margaret Madeleine (USA)

How to optimize cervical cancer screening among women living with HIV • Anna Giuliano (USA)

HPV-related disease in transgender and non-binary individuals • Hanna Milerad (Sweden) - Tim J. Palmer (UK) - Anna-Barbara Moscicki (USA)

Behavioral science, trust, hesitancy and patient-centered outcomes • Ilya Olkov (France) - Efraim Siegler (Israel)

HPV research in Central and Eastern Europe: Great success with scarce resources • Mario Poljak (Slovenia) - Andrzej Nowakowski (Poland)

Debate session • Kate Cuschieri (UK) - Tim Palmer (UK)